Can constipation drugs reveal hidden signals in gut tissue?
NCT ID NCT05107219
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study looked at how two approved constipation drugs, plecanatide and linaclotide, affect a chemical called cGMP in the small intestine. Researchers compared tissue samples from 43 adults with Barrett esophagus or GERD who took either drug or no drug. The goal was to measure cGMP levels, not to treat any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BARRETT ESOPHAGUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a tailored diet quiet the burn of acid reflux?
- Can surgery offer lasting relief for chronic heartburn? a large registry investigates
- Can big data unlock better GERD treatment for chinese patients?
- Which Anti-Reflux surgery is kinder to a Child's stomach?
- Which biopsy method best spots early esophageal cancer?
- New cutting tool may outperform heat therapy for Barrett's esophagus